Solifenacin
Total Payments
$23,632
Transactions
4
Doctors
0
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $23,632 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23,632 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| IMPACT - Incontinence & IntiMate Partners: Assessing the Contribution of Treatment | Astellas Pharma Global Development | $22,132 | 0 |
| A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder | Astellas Pharma Europe BV | $1,500 | 0 |
Top Doctors Receiving Payments for Solifenacin
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Poughkeepsie, NY | $23,632 | 4 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $22,132
- Astellas Pharma Europe BV $1,500
Product Information
- Type Drug
- Total Payments $23,632
- Total Doctors 0
- Transactions 4
About Solifenacin
Solifenacin is a drug associated with $23,632 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2017. In 2017, $23,632 was paid across 4 transactions to 0 doctors.
The most common payment nature for Solifenacin is "Unspecified" ($23,632, 100.0% of total).
Solifenacin is associated with 2 research studies, including "IMPACT - Incontinence & IntiMate Partners: Assessing the Contribution of Treatment" ($22,132).